Victory Capital Management Inc. Buys 4,728 Shares of Xencor, Inc. (NASDAQ:XNCR)

Victory Capital Management Inc. boosted its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 26.6% during the third quarter, Holdings Channel.com reports. The firm owned 22,504 shares of the biopharmaceutical company’s stock after purchasing an additional 4,728 shares during the quarter. Victory Capital Management Inc.’s holdings in Xencor were worth $735,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Baillie Gifford & Co. raised its stake in Xencor by 39.3% in the third quarter. Baillie Gifford & Co. now owns 1,259 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 355 shares during the last quarter. Lazard Asset Management LLC raised its stake in Xencor by 43.0% in the second quarter. Lazard Asset Management LLC now owns 1,833 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 551 shares during the last quarter. Amundi purchased a new stake in Xencor in the second quarter valued at about $138,000. Nisa Investment Advisors LLC raised its stake in Xencor by 718.7% in the third quarter. Nisa Investment Advisors LLC now owns 4,912 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 4,312 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in Xencor by 145.4% in the second quarter. Royal Bank of Canada now owns 5,417 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 3,210 shares during the last quarter. 98.16% of the stock is currently owned by institutional investors.

Shares of XNCR stock opened at $37.05 on Friday. The stock has a 50 day moving average of $37.72 and a 200 day moving average of $35.62. The stock has a market cap of $2.17 billion, a P/E ratio of -370.50 and a beta of 0.76. Xencor, Inc. has a twelve month low of $30.12 and a twelve month high of $58.35.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Monday, November 8th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.06. The company had revenue of $19.68 million during the quarter, compared to analysts’ expectations of $17.63 million. Xencor had a negative return on equity of 0.68% and a negative net margin of 2.53%. During the same period last year, the business earned ($0.22) earnings per share. Research analysts anticipate that Xencor, Inc. will post 0.62 EPS for the current year.

A number of equities research analysts have commented on XNCR shares. Zacks Investment Research cut Xencor from a “buy” rating to a “hold” rating in a research note on Friday, November 12th. BTIG Research reiterated a “buy” rating on shares of Xencor in a research note on Tuesday, November 9th. Guggenheim decreased their price target on Xencor from $57.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, September 28th. Piper Sandler reduced their price objective on Xencor from $75.00 to $71.00 and set an “overweight” rating for the company in a research note on Tuesday, November 9th. Finally, TheStreet cut Xencor from a “c” rating to a “d+” rating in a research note on Friday, November 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $52.67.

In related news, CMO Allen Yang sold 3,664 shares of Xencor stock in a transaction that occurred on Friday, December 17th. The stock was sold at an average price of $36.62, for a total transaction of $134,175.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.68% of the stock is currently owned by company insiders.

About Xencor

Xencor, Inc engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.

Recommended Story: Forex

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.